Table 2.
Treatment information for patients with advanced disease at presentation managed with first-line chemotherapy (n=34).
| N=34 | |
|---|---|
| IGCCCG risk group, n (%) | |
| Good | 21 (62) |
| Intermediate | 8 (24) |
| Poor | 5 (15) |
| Chemotherapy regimen, n (%) | |
| BEP x 3 | 4 (12) |
| BEP x 4 | 12 (35) |
| EP x 4 | 16 (47) |
| HDCT/ASCT | 1 (2.9) |
| VIP x 4 | 1 (2.9) |
| Biopsy pre-chemotherapy, n (%) | 31 (91) |
| Elevated markers at any point prior to chemotherapy1, n (%) | 22 (81) |
| AFP (N=27) | 4 (15) |
| HCG (N=26) | 15 (58) |
| LDH (N=26) | 19 (73) |
1
Any pre-treatment tumor markers were available in 27 patients (either pre- or post-orchiectomy but prior to initiation of chemotherapy).
IGCCCG: International Germ Cell Cancer Collaborative Group; BEP: bleomycin, etoposide, and cisplatin; EP: etoposide and cisplatin; HDCT/ASCT: high dose chemotherapy and autologous stem cell transplant; VIP: etoposide, ifosfamide, and cisplatin; AFP: alpha-fetoprotein; HCG: human chorionic gonadotropin; LDH: lactate dehydrogenase.